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The brain is composed of many lipids with varied forms that serve not only as structural components but also
as essential signaling molecules. Lysophosphatidic acid (LPA) is an important bioactive lipid species that is
part of the lysophospholipid (LP) family. LPA is primarily derived from membrane phospholipids and signals
through six cognate G protein-coupled receptors (GPCRs), LPA1-6. These receptors are expressed on most
cell types within central and peripheral nervous tissues and have been functionally linked tomany neural pro-
cesses and pathways. This Review covers a current understanding of LPA signaling in the nervous system,
with particular focus on the relevance of LPA to both physiological and diseased states.Introduction
The human brain is composed of approximately 60%–70% lipids
by dry weight (Svennerholm et al., 1994). These lipids can be
divided into two major pools, structural and signaling, which
include well-known families such as cholesterol, fatty acids, ei-
cosanoids, endocannabinoids, and prostaglandins (Figure 1).
Structural lipids classically comprise cell membranes and may
be passively organized by protein factors (reviewed in Rossy
et al., 2014), whereas signaling lipids function in a predominantly
extracellular fashion through receptors to activate downstream
pathways (reviewed in Bieberich, 2012). Lysophospholipids
(LPs) are an important family of lipid signalingmolecules, and lyso-
phosphatidic acid (LPA) is a major member of this family, present
in numerous tissues and fluids, notably within the developing and
adult nervous system. LPA effects are now known to act through
cognate, cell-surface GPCRs termed LPA receptors (LPARs, re-
viewed inNoguchi et al., 2009;Choi et al., 2010; Yung et al., 2014).
Since the discovery of the first LP receptor for LPA in the
developing brain (Hecht et al., 1996), five other LPARs have
been characterized and all are expressed in the nervous system
(Figure 2). Many roles for LPA signaling have been elucidated,
including effects on neuroprogenitor cell (NPC) function (Hecht
et al., 1996; Yung et al., 2011), myelination (Weiner et al., 1998;
Fukushima et al., 2002b; Anliker et al., 2013), synaptic transmis-
sion (Trimbuch et al., 2009), and brain immune responses (Mo¨ller
et al., 2001; Schilling et al., 2004), which influence neural devel-
opment, function, and behavior (Figure 3). Additionally, LPA
signaling is important in endothelial cell and neurovascular
function (Yukiura et al., 2011; and reviewed in Teo et al., 2009).
LPARdiscovery also led to the identification of another LP recep-
tor subclass, sphingosine 1-phosphate (S1P) receptors, which
bind this distinct LP (Kihara et al., 2014a). S1P and its five recep-
tors also have important nervous system activities (Mizugishi
et al., 2005; Meng et al., 2011; van Echten-Deckert et al.,
2014), but they will not be covered here.
The ecosystem of neural LPA signaling has been considerably
expanded with the characterization of both LPA precursors andLPA synthesis/degradative enzymes (reviewed in Sigal et al.,
2005; Brindley and Pilquil, 2009; Perrakis and Moolenaar,
2014). In view of the broad neurobiological influences of LPA
signaling, its dysregulationmay lead to diverse neuropathologies
(Bandoh et al., 2000; Houben and Moolenaar, 2011; Yung et al.,
2011; Ueda et al., 2013). LPs and their relevance to non-nervous
system tissues have been reviewed elsewhere (Choi et al., 2010;
Mirendil et al., 2013).
LPA Metabolism and Distribution
LPA is a metabolite in the biosynthesis of membrane phospho-
lipids and is ubiquitously present in all examined tissues. The
generic term LPA (mono-acyl-sn-glycerol-3-phosphate) often
refers to 18:1 oleoyl-LPA (1-acyl-2-hydroxy-sn-glycero-3-phos-
phate), reflecting its widespread laboratory use. However, many
other chemical forms of LPA with different acyl chain lengths,
saturation, and position also exist. The tissue distribution of
LPA and its metabolites are relevant to both basic and medical
applications (reviewed in Yung et al., 2014). LPA is prominently
found in blood fractions, where it ranges from 0.1 mM in plasma
to more than 10 mM in serum. These concentrations are sig-
nificantly higher than the estimated nanomolar Kd values of
LPA1-6 (Aoki et al., 2002; Hosogaya et al., 2008; Yanagida
et al., 2009).Within the CNS, LPA is found in the embryonic brain,
neural tube, choroid plexus, meninges, blood vessels, spinal
cord, and cerebrospinal fluid (CSF) at low nanomolar to micro-
molar concentrations (reviewed in Yung et al., 2014). Total LPA
can be measured via multiple assays (Hosogaya et al., 2008; Je-
sionowska et al., 2014), while individual chemical forms can be
identified by chromatography coupled to mass spectrometry
(Triebl et al., 2014). Such techniques are proving useful in analyt-
ical and diagnostic settings (Hosogaya et al., 2008; Okudaira
et al., 2010; Yung et al., 2011).
LPA is generated through several different enzymatic path-
ways (Figure 1). Amajor pathway is through the enzymatic action
of autotaxin (ATX) (Tanaka et al., 2006; van Meeteren et al.,
2006). Constitutive removal of ATX (gene name: Enpp2) resultsNeuron 85, February 18, 2015 ª2015 Elsevier Inc. 669
Figure 1. LPA Is a Bioactive Lipid that
Signals through Defined GPCRs within the
Nervous System
Lipids comprise a significant portion of the CNS
and have differing structural, energetic, and
bioactive signaling properties. Signaling lipids are
often bound to carrier proteins such as albumin or
heat shock proteins. LPA activates members of a
family of G protein-coupled receptors (GPCRs) and
influences multiple cellular processes including
proliferation, survival, apoptosis, morphological
change, and migration, as well as the production of
other lipids such as prostaglandins through arach-
idonic acid (AA) conversion by cyclooxygenase-2
(COX-2). The synthetic pathways for LPA include
conversion of phosphatidylcholine (PC) into lyso-
phosphatidylcholine (LPC) by lecithin-cholesterol
acyltransferase (LCAT) and phospholipase A (PLA)
1 enzymes, or by conversion of PC to phosphatidic
acid (PA) by phospholipase D (PLD). LPC is then
metabolized to produce lysophosphatidic acid
(LPA) by the enzyme autotaxin (ATX). LPA can be
broken down into monoacylglycerol (MAG) by a
family of lipid phosphate phosphatases (LPPs).
Chemical structures are shown to highlight acyl
chain composition but do not reflect actual 3-D
geometries. Other lipids in the CNS include the
endocannabinoid family, fatty acids, cholesterol,
and prostaglandins, which are beyond the scope of
this Review.
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9.5 (Tanaka et al., 2006; van Meeteren et al., 2006). Enpp2
heterozygous null mice have 50% reduced LPA in plasma
(van Meeteren et al., 2006; Fotopoulou et al., 2010). In addition,
Enpp2 conditional deletion from epiblasts mediated by Cre re-
combinase under the control of Sox-2 gene regulatory elements
results in neural tube defects (Fotopoulou et al., 2010). ATX
structure, splice variants, and functional domains are being
actively examined (reviewed in Perrakis and Moolenaar, 2014).
A second major pathway generates LPA from membrane phos-
pholipids through the actions of phospholipases (Aoki et al.,
2002). There are additional pathways for generating LPA, partic-
ularly involving acyltransferases (reviewed in Page`s et al., 2001).
The generated LPA forms reflect their precursor phospholipid
structure (e.g., 18:1 lysophosphatidylcholine [LPC] produces
18:1 LPA) (Aoki, 2004). These pathways generate both intracel-
lular and extracellular LPA (reviewed in Page`s et al., 2001). Extra-
cellular LPA produces signaling through its receptors (reviewed
in Choi et al., 2010; Yung et al., 2014 and noted below), while
intracellular LPA serves as an intermediate for the de novo
biosynthesis of complex glycerolipids (reviewed in Page`s et al.,
2001). Additionally, these lipid pools can affect membrane vesic-
ular curvature (McMahon and Gallop, 2005).
LPA can be degraded by liberation of the phosphate group to
produce monoacylglycerol (MAG), mediated by several classes
of enzymes, including lipid phosphate phosphatases (LPPs)
(also called phosphohydrolases) (Brindley and Pilquil, 2009),
LPA acyltransferase (LPAAT), lecithin-cholesterol acyltransfer-
ase (LCAT), and other lipid enzymes (reviewed in Page`s et al.,670 Neuron 85, February 18, 2015 ª2015 Elsevier Inc.2001; Aoki et al., 2002; Aoki, 2004). Inhibi-
tion of LPP(1-3)-mediated degradation
can elevate LPA levels in cerebral corticaltissue (Aaltonen et al., 2012). It has been difficult to spatiotempo-
rally map LPA and relatedmetabolites in specific cell types in the
nervous system, particularly critical in light of the identified
spatiotemporal distributions of LPARs. However, this is an area
of active research that will benefit from emerging technologies.
LPARs
There are currently six LPARs: protein names LPA1–LPA6 with
gene names LPAR1-LPAR6 (human) and Lpar1-Lpar6 (non-hu-
man) (reviewed in Chun et al., 2010; Kihara et al., 2014a; Yung
et al., 2014). These 7-transmembrane GPCRs activate hetero-
trimeric G proteins defined in part by their Ga subunits (G12/13,
Gq/11, Gi/o, and Gs) to initiate various signaling cascades. During
development, the cell types comprising the brain arise from
distinct lineages and undergo cellular processes: these include
proliferation, apoptosis, morphological changes, migration,
and differentiation into cells with specialized functions underly-
ing neural networks (Greig et al., 2013). LPARs are expressed
in varying spatiotemporal patterns from fetal through mature
life (Figure 2). LPA signaling drives diverse physiological and
pathophysiological processes within the nervous system
(Figure 3).
Fetal Cerebral Cortical Development
During cerebral cortical development, neuroepithelial cells prolif-
erate to give rise to the ventricular zone (VZ), subventricular zone
(SVZ), intermediate zone (IZ), cortical plate, and marginal zone
(MZ) (Figure 2). NPCs that reside in the VZ undergo interkinetic
nuclear migration (INM) and proliferate to generate distinct
Figure 2. LPAR Subtypes in the Developing and Mature Cerebral Cortex
Reported LPAR subtype expression of the six LPA receptors, LPA1-6, varies with developmental age and cell type. Left: LPARs are expressed in neural progenitor
cells (NPCs) and other developing cortical cells. These expression patterns vary as the progenitors arise in the ventricular zone (VZ) and differentiate as they
migrate through the subventricular zone (SVZ) and intermediate zone (IZ), to localize within the cortical plate (CP). In the embryonic brain, LPA-mediated pro-
cesses include proliferation, interkinetic nuclear migration, neurite retraction, survival, morphological change, and cell migration. Right: most major cell types in
the mature cortex express specific subtypes of LPARs. LPARs are also expressed in cells of the ependyma, blood-brain barrier, and meninges, which overlie the
most superficial marginal zone (MZ). Postnatally, LPA signaling influences myelination, microglial and astrocytic responses, vascular stabilization, and higher
cognitive processes.
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migrate superficially to locate within cell layers and establish
functional connections (reviewed in Taverna et al., 2014). As-
trocytes and oligodendrocytes are generated during late embry-
onic and early postnatal periods, and together with neurons,
comprise basic cellular elements of the cortex, complemented
by other cell types such as endothelial cells, pericytes, ependy-
mal cells, microglia, meninges, and cells of the choroid plexus
(Figure 2).
Enrichment of Lpar1 in the VZ and meninges of the developing
cortex suggests roles for LPA signaling in cortical development,
as reflected in its original name, ventricular zone gene-1 (VZG1)
(Hecht et al., 1996). The characterization of LPAR null mice has
critically helped to elucidate the LPAR dependency of diverse
LPA-associated neural phenotypes. Constitutive deletion of
Lpar1 results in 50% perinatal lethality associated with olfactory
and other nervous system defects (Contos et al., 2000; Harrison
et al., 2003). Ex vivo whole cerebral cortical cultures treated with
LPA form thicker cortices through decreased cell death within
the VZ (rather than through increasing cell proliferation) andhave an increased post-mitotic neuronal population (Kingsbury
et al., 2003). Concomitant removal of Lpar1 and Lpar2 prevents
these effects, demonstrating receptor dependency. Meninges at
E13, as assessed by mouse embryonic meningeal fibroblasts
(MEMFs), respond to the addition of LPA by the formation
of actin-based stress fibers (Contos et al., 2002). Deletion of
both, but not single, Lpar1 and Lpar2 prevents formation of
LPA-induced MEMF stress fibers (Contos et al., 2002).
LPA has multiple effects on NPCs. Calcium conductance
changes are mediated by LPA signaling and occur before ionic
responsivity induced by neurotransmitters such as GABA and
glutamate (Dubin et al., 1999, 2010). Electrical fluctuations based
on calcium signaling are known to impact NPC proliferation,
neuronal differentiation, chemotaxis, dendritic morphology,
axon growth and guidance, and neurotransmitter phenotype (re-
viewed in Rosenberg and Spitzer, 2011), all of which can be influ-
enced by LPA signaling.
INM is the to-and-fro movement of nuclei from apical to basal
positions in the VZ during cell-cycle progression. Ex vivo and
in vivo cortical exposure to LPA disturbs INM by increasing theNeuron 85, February 18, 2015 ª2015 Elsevier Inc. 671
Figure 3. Dysregulated LPA Signaling May Lead to Nervous System Disorders
Aberrant LPA signaling, whether produced by overactivation, altered LPA production/degradation, or changes in receptor expression, can disrupt the nervous
system to produce sequelae relevant to human brain disorders.
(A) LPA signaling has been linked to post-hemorrhagic hydrocephalus. Amousemodel recapitulatesmultiple histological comorbidities seen in humans, including
ventriculomegaly, thinning of the cortical plate (CP), formation of neurorosettes, disrupted NPCswithin the ventricular zone (VZ) and intermediate zone (IZ), loss of
cell adhesion that leads to the presence of free-floating cells in the CSF, compromised ependymal lining, and ventricular occlusions. Hydrocephalus is often
chronic, with increased CSF pressure, ventriculomegaly, and decreased brain mass persisting throughout postnatal life.
(B) Lpar1 null mice display dysregulated neural signaling, with disruption of glutamatergic (AMPA and NMDA receptor expression and composition) and
GABAergic (GABA+/PV+ neuron decreases) function, leading to significant cognitive impairments in animal models.
(C) Nerve damage induces the production of LPA via ATX-mediated conversion of LPC. LPA stimulates LPA3 on activatedmicroglia, resulting in feedforward LPA
release that, in turn, can activate LPA1 on Schwann cells, leading to downregulation of myelin proteins, progressive demyelination, and initiation of neuropathic
pain.
(D) Brain tumors often overexpress ATX and LPARs, leading to altered LPAR signaling. LPA1-3 stimulation by increased environmental LPA induces cell migration
and promotes cancer cell metastasis.
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in mitotic displacement (Kingsbury et al., 2003; Yung et al.,
2011). Mitotic displacement also occurs in an Lpar1-dependent
manner under hypoxic culture conditions (Herr et al., 2011).
Future studies could refine the understanding of LPA signaling
on specific progenitor populations in this context, such as apical,
basal, or intermediate progenitors, or outer subventricular zone
radial glia-like cells (Taverna et al., 2014).
A hallmark of cortical development is the migration of newly
generated neurons to their final superficial location within the
cortical plate. This migration is aided by leading processes that
help sense the surrounding environment for signaling cues,672 Neuron 85, February 18, 2015 ª2015 Elsevier Inc.such as growth factors, chemoattractants, and chemorepel-
lents. In vitro studies utilizing the B103 cell line, wild-type E12
embryonic nestin-positive cortical progenitor cells, and E12
cortical explant cultures identified protruding lamellipodia and
growth cones that rapidly retracted upon LPA exposure in a
Rho-dependent manner, leaving fine F-actin retraction fibers.
This supports LPA’s role as an inhibitory cue during cell migra-
tion or process outgrowth (Fukushima et al., 2002b; Campbell
and Holt, 2003).
During corticogenesis, programmed cell death can affect sig-
nificant populations of developing cells (Blaschke et al., 1996,
1998; Yung et al., 2009). Culturing ex vivo cortices in LPA
Neuron
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(Kingsbury et al., 2003). LPA signaling activates cell survival
pathways, including thymoma viral proto-oncogene (Akt)
(Weiner and Chun, 1999) and b-catenin (Weiner et al., 2001).
Moreover, b-catenin and T cell factor signaling can be activated
by LPA and can contribute to the suppression of apoptosis in
H197 cells (an embryonic hippocampal progenitor cell line)
(Sun et al., 2013). LPA signaling has also been reported to influ-
ence neurosphere proliferation in culture (Svetlov et al., 2004).
NPCs express multiple LPAR subtypes (Figure 2) and LPA
signaling can influence their development and function.
Neurons
In mice, cortical neurogenesis extends from E10 to E18, during
which NPCs divide to produce other progenitors and young
postmitotic neurons. LPA promotes cortical NPCs to commit
to the neuronal lineage via LPA1 and the Gi/o pathway (Kingsbury
et al., 2003; Fukushima et al., 2007). Additionally, LPA can alter
the actin cytoskeleton and promote microtubule rearrangement
within neurons (Fukushima et al., 2002a; Fukushima and Morita,
2006) as well as influence the morphology and motility of young
postmitotic neurons (Fukushima et al., 2002b). Neurite retraction
(Hecht et al., 1996), an important response to chemical gradi-
ents, can be mediated by LPA via the ROCK pathway (Tigyi
et al., 1996). More recently, transient receptor potential channel,
subfamily M, member 2 (TRPM2) was reported to mediate
LPA-induced neurite retraction in the developing brain (Jang
et al., 2014). Finally, neurite branching, an important process
for neuronal network formation, was induced through the intro-
duction of LPA3 and the addition of LPA into hippocampal cell
cultures (Furuta et al., 2012). This physiological response was
initiated through Gq and the Rho family GTPase 2 (Rnd2) (Furuta
et al., 2012).
Maturing neurons establish polarity through the specification
and development of neurites into axons and dendrites. In hippo-
campal neuronal cultures, axonal bases were predominantly
found distal to an exogenous LPA source (Yamane et al.,
2010). Localization of the Golgi apparatus and centromeres,
which are associated with the establishment of neuronal polarity
before axonogenesis (de Anda et al., 2005), were also positioned
distal to the LPA source, suggesting that LPA signaling can influ-
ence the site of axonal sprouting (Yamane et al., 2010). Lpar6,
the most recently characterized LPAR family member, is en-
riched in the neural plate of Xenopus neurulae. Deletion of
Lpar6 results in forebrain defects with concomitant reduction
of telencephalic markers, as well as defects extending into the
hindbrain (Geach et al., 2014). The roles of Lpar6 in the develop-
ment and function of the mammalian nervous system remain to
be characterized, although human mutations of this receptor
gene have most notably been associated with forms of hair
loss (Pasternack et al., 2008).
Astrocytes
In vivo, astrocytes appear to express few LPA receptor subtypes
aside from low levels of Lpar1 (Tabuchi et al., 2000; Weiner et al.,
2001; Cervera et al., 2002), whereas cultured astrocytes express
Lpar1-5 (Sorensen et al., 2003; Shano et al., 2008). Receptor
subtype expression depends on age, species (Rao et al.,2003), and cell activation state. The expression of newly classi-
fied Lpar6 in astrocytes remains to be examined.
During development, LPA has numerous effects on cultured
astrocytes, including intracellular calcium mobilization (Tabuchi
et al., 2000), generation of reactive oxygen species, and actin
cytoskeletal rearrangement (Spohr et al., 2008). Most studies
have shown LPA-mediated DNA synthesis and proliferation in
astrocytes (Ramakers and Moolenaar, 1998; Sorensen et al.,
2003; Shano et al., 2008), although some conflicting reports exist
that may be a function of the employed LPA concentration
(Fuentes et al., 1999; Shano et al., 2008), astrocyte origin, spe-
cies, or cell selection in culture (Pe´bay et al., 1999; Furukawa
et al., 2007). Additionally, LPA can induce astrocytes to express
immediate-early genes through pertussis-toxin sensitive G pro-
teins, as well as cytokine genes, including nerve growth factor
(NGF), interleukin (IL)-1b, IL-3, and IL-6 (Tabuchi et al., 2000).
In culture, cross-talk between neurons and astrocytes through
LPA signaling has been reported. For example, LPA-activated
astrocytes can induce neuronal differentiation (Spohr et al.,
2008) as well as axonal outgrowth of neurons via extracellular
matrix proteins and the epidermal growth factor signaling
pathway (Spohr et al., 2011). The production of NGF can also
be enhanced by astrocytic exposure to LPA and other LPs (Fur-
ukawa et al., 2007). Astrocyte proliferation and astrogliosis
appear to be influenced by LPA signaling, probably through
Lpar1-3 (Sorensen et al., 2003). Finally, stimulation of astrocytes
by lipopolysaccharide (LPS) or IL-1b, induces LPA-responsive
astrocyte migration (Sato et al., 2011). It is likely that other
LPA-induced paracrine signals exist among cell types within
the nervous system.
Oligodendrocytes
Oligodendrocytes are CNSmyelinating glia that express Lpar1 in
a spatiotemporal manner that correlates with maturation and
myelination, peaking between postnatal day (P) 15 and P21 in
mice (Weiner et al., 1998). In vitro, LPA induces calcium mobili-
zation, extracellular-regulated-kinase 1/2 (ERK1/2) phosphory-
lation, process retraction, and cell rounding in mature oligoden-
drocytes, but not in oligodendrocyte precursors (Mo¨ller et al.,
1999). Early studies reported that Lpar1 in oligodendrocytes
did not promote myelination (Stankoff et al., 2002). However, a
subsequent study supports a role for LPA signaling on the tran-
sition from process outgrowth to membrane sheath formation as
oligodendrocytes switch from premyelinating to myelinating
forms (Nogaroli et al., 2009). The maintenance of Lpar1 in oligo-
dendrocytes does not appear to require an axonal signal from
neurons, suggesting that it is regulated by an intrinsic oligoden-
drocyte program (Stankoff et al., 2002). Finally, LPA stimulates
process formation and increases the number of differentiating,
but not mature, oligodendrocytes (Nogaroli et al., 2009).
Schwann Cells
Schwann cells (SCs) are peripheral myelinating glia that are also
responsive to LPA signaling. At least three types of SCs exist.
Myelinating SCs form the myelin sheath around axons and ex-
press Lpar1 and possibly Lpar2. Perisynaptic SCs (also called
terminal SCs) are present at the neuromuscular junction, express
both Lpar1 and Lpar3 (Weiner et al., 2001; Kobashi et al., 2006),Neuron 85, February 18, 2015 ª2015 Elsevier Inc. 673
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esis, and nerve regeneration (Armati and Mathey, 2013). The
expression of LPARs in non-myelinating SCs, which ensheathe
non-myelinated fibers, is currently unknown. LPA1 signaling re-
duces SC death through Gi, phosphatidylinositol-4,5-bisphos-
phate 3-kinase (PI3K), and Akt in vitro (Weiner and Chun,
1999), which is supported in vivo by observations that Lpar1
null mice have increased apoptosis of SCs in sciatic nerves
(Contos et al., 2000).
In addition to promoting SC survival, LPA also induces dy-
namic alterations to the actin cytoskeleton, with corresponding
morphological and cell adhesion changes (Weiner and Chun,
1999; Weiner et al., 2001). In vitro, the effects of LPA on SCs
include promoting wreath formation, activating N-cadherin-
dependent cell aggregation, and enhancing focal adhesions.
These responses are dramatically reduced in Lpar1 null SCs
(Weiner et al., 2001). P0 protein, a glycoprotein that is a major
structural component of the myelin sheath, can be increased in
SCs by LPA2 signaling, which may contribute to SC differentia-
tion (Li et al., 2003). Recently, it was shown that LPA via LPA1
signaling coupled to Gi and Rac1 can promote embryonic SC
migration, myelination, and cell-to-axon segregation. By con-
trast, Lpar1 null mice showed delayed SC-to-axon segregation,
abnormal polyaxonal myelination, and thinner myelin sheaths
(Anliker et al., 2013).
In adult SCs isolated from axotomized sciatic nerve, Lpar1 and
Lpar2 are coincidentally upregulated during post-axotomy SC
proliferation, suggesting that LPA signaling promotes SC divi-
sion in regenerating peripheral nerves (Weiner et al., 2001; Froh-
nert et al., 2003). In contrast, exogenous LPA induces demyelin-
ation of neurons in dorsal root ex vivo culture as well as in mice
that have been intrathecally injectedwith LPA (Inoue et al., 2004).
Microglia
Microglia, derived from hematopoietic stem cells, are the resi-
dent macrophages of the CNS, showing multiple types and
activation states including ramified (resting or quiescent) or acti-
vated. Activated microglia can scavenge, present antigens,
phagocytose, and release inflammatory mediators during injury
and neurodegeneration (Hu et al., 2014). Microglia from mouse
or rat mainly express Lpar1 and/or Lpar3 (Mo¨ller et al., 2001;
Tham et al., 2003), while human microglial cell lines express
LPAR1-3 (Mo¨ller et al., 2001; Bernhart et al., 2010). Receptor
activation by LPA can induce intracellular calcium mobilization
and potassium channel activation, as well as cell proliferation,
cell morphology changes, upregulated chemokinesis, and
membrane ruffling (Schilling et al., 2004; Fujita et al., 2008;
Muessel et al., 2013). GPCR reciprocal modulation by both
LPA and stromal cell-derived factor-1 (SDF-1) on their respec-
tive receptors produces microglial morphological changes
through inward-rectifier potassium channel 2.1 (Kir2.1) modula-
tion, although the specific LPAR subtype remains to be defined.
As with other cell types in the brain, LPAR profiles and re-
sponses probably vary with microglia maturation, activation
state, and species source. Recent distinctions between brain
macrophage and microglia function (reviewed in Prinz and Pril-
ler, 2014) probably involve LPARs; further studies in this area are
needed.674 Neuron 85, February 18, 2015 ª2015 Elsevier Inc.Choroid Plexus
The choroid plexus is the major site of CSF production. It con-
sists of epithelial cells surrounding a central area with capillaries
and is contiguous with the ependymal layer. Unlike the epen-
dyma, the choroid plexus is structurally distinct with tight gap
junctions that connect the apical surface of the epithelial cells
(reviewed in Johansson, 2014). Lpar5 appears in the fourth ven-
tricular choroid plexus of themouse embryo (Ohuchi et al., 2008).
LPAR6 is expressed in human lateral ventricular choroid plexus,
and reduced expression is seen in major depressive disorder
(Turner et al., 2014). Importantly, LPA-related metabolic en-
zymes such as ATX are highly expressed in the choroid plexus
(Ba¨chner et al., 1999; Savaskan et al., 2007). The presence of
ATX in the choroid plexus, and the general proximity of the
choroid plexus to neurogenic structures, may catalyze blood-
derived LPC into bioactive LPA that can affect many aspects
of neurodevelopment.
Brain Vasculature
Development of the nervous system occurs in tandem with
establishment of the vascular network, which encompasses vas-
culogenesis, angiogenesis, vessel maturation and stability, as
well as blood-brain barrier (BBB) formation (Greenberg and Jin,
2005; Eichmann and Thomas, 2013). Vascular factors such
as vascular endothelial growth factor (VEGF), platelet-derived
growth factor (PDGF), andNotch have roles in CNS development
(Eichmann and Thomas, 2013; Ruhrberg and Bautch, 2013). In
parallel, LPARs and LPA signaling can also influence vascular
biology (Teo et al., 2009). Notably, LPA and VEGF signaling are
intertwined: LPA can induce VEGF expression via NF-kB
signaling, and VEGF can induce ATX and Lpar1 expression in
endothelial cells (Lin et al., 2008; Ptaszynska et al., 2010; Dutta
et al., 2011).
Studies linking LPA to vascular development demonstrated
that ATX null mice die by E9.5 with vascular defects (Tanaka
et al., 2006; van Meeteren et al., 2006). These defects are similar
to those found in G13 null mice (Offermanns et al., 1997); LPA re-
ceptor subtypes are known upstream activators of G12/13 (Yung
et al., 2014). Indeed, Lpar1-null and Lpar2 null mice have
vascular defects, such as frontal cerebral hematomas (Contos
et al., 2000, 2002). Additionally, Lpar4 null mice have impaired
pericyte recruitment related to dilated blood and lymphatic ves-
sels (Sumida et al., 2010). Pericytes appear to mediate blood
vessel stabilization by increasing the rate of LPA degradation,
based upon an in vitro model of angiogenesis (Motiejunait _e
et al., 2014).
Cultured endothelial cells (ECs) have been shown to express
LPAR1-6 (Lin et al., 2007; Schleicher et al., 2011; Ren et al.,
2013). LPA promotes the survival and proliferation of ECs from
a variety of sources (English et al., 1999), including brain micro-
vascular bEND.3 cells (Schleicher et al., 2011). LPA can also
stimulate EC migration (English et al., 1999; Wu et al., 2005)
and influence vascular tone. An early report, using a piglet model
of intracranial hematoma demonstrated that LPA exposure pro-
duces dose-dependent vasoconstriction, which is reminiscent of
that produced by hemorrhage (Tigyi et al., 1995). More recently,
LPA has been found to mediate vasodilation via LPA1, phospho-
lipase C, and endothelial nitric oxide synthase (Ruisanchez et al.,
Neuron
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permeability (On et al., 2013; Yu et al., 2014), as may occur dur-
ing pathological conditions like stroke.
Stressors and Neuropsychiatric Disorders
CNS Injury
Beyond development and normal function of the nervous sys-
tem, LPAR signaling is also important during CNS stress or dam-
age. During injury, LPA concentrations in brain and CSF are
significantly elevated (Tigyi et al., 1995; Goldshmit et al., 2010)
and can reach thousands of times the apparent Kd of LPA recep-
tors (Yung et al., 2011). Traumatic injury can induce LPA2 gene
expression in human ependymal cells as well as mouse cortical
and spinal cord astrocytes (Goldshmit et al., 2010; Frugier et al.,
2011). Lpar1 is also increased in reactive murine spinal cord
astrocytes, while Lpar3 expression is reportedly increased in
cortical and spinal cord neurons (Goldshmit et al., 2010). Addi-
tionally, ATX levels in the human cerebral cortex are decreased
after fatal closed head injury (Frugier et al., 2011). Whether this
is due to negative feedback from injury-mediated LPA release
(van Meeteren et al., 2005) or other factors remains to be deter-
mined. Conversely, ATX levels are dramatically increased in
whitematter adjacent to injury lesions in the rat cortex (Savaskan
et al., 2007), suggesting possible overactive LPA signaling. Re-
ported use of anti-LPA antibodies to improve CNS injury out-
comes (Crack et al., 2014) are consistent with pathological roles
of increased LPA signaling, although mechanistic validation of
this approach awaits further study.
Hypoxia
Ischemia is a major cause of hypoxia, which results in decreased
synaptic transmission, inflammation, and neural death (Corcoran
and O’Connor, 2013). LPA1 signaling has been tied to hypoxia
through distinct mechanisms. For instance, hypoxia enhances
LPA-induced hypoxia inducible factor-1 alpha (HIF-1a) expres-
sion in cancer cells and VEGF expression in the vasculature
(Lee et al., 2006, 2013). Embryonic HIF-1a expression is also
dependent on the presence of ATX and is rescued by LPA expo-
sure in ATX null animals (Fotopoulou et al., 2010). Hypoxia can
alter brain development and result in neurological disability or
psychiatric disease; even short-term cortical exposure to low ox-
ygen levels causes cellular abnormalities that include overactiva-
tion of LPA1 and downregulation of G protein-coupled receptor
kinase 2 (GRK2) (Herr et al., 2011). These abnormalities were
previously seen upon stimulation of LPA1 signaling in NPCs
(Kingsbury et al., 2003) and could be reduced or prevented by
an LPA1/3 inhibitor, use of Lpar1 null mice (Herr et al., 2011), or
use of Lpar1 and Lpar2 double null mice (Kingsbury et al.,
2003). Similar protection against mitotic displacement produced
by hypoxia was seen with inhibition of Rac1, Rho-associated
kinase (ROCK), and HIF-1a, indicating that these signaling mol-
ecules may be involved in this Lpar1-dependent pathway (Foto-
poulou et al., 2010).
In postnatal brains, hypoxia can be caused by stroke or
trauma (Corcoran and O’Connor, 2013). Increased LPA signaling
promotes retinal cell survival under hypoxic conditions by upre-
gulation of Lpar1 and Lpar2 expression in ganglion cells and the
inner retinal layers (Savitz et al., 2006). However, retinopathy
models of prematurity in rat neonates, produced by alternatingcycles of hypoxia and hyperoxia, showed conflicting results
(Yang et al., 2009): while Lpar1 was upregulated in retinal tissue,
LPA exposure or Lpar1 overexpression decreased cell viability
and LPA1 inhibition or short hairpin RNA knockdownwas protec-
tive to cell survival. LPAR signaling is clearly involved during hyp-
oxia with ischemic insult, although continued investigation will be
necessary to resolve LPA’s role as a protective or harmful factor.
Hydrocephalus
Several neurological disorders are strongly correlated with a pre-
ceding hemorrhagic event during development, possibly result-
ing in enhanced LPA signaling through blood exposure. Fetal hy-
drocephalus, one of the most common neurological diseases of
perinatal life, has been linked to overactivation of LPA signaling
in an embryonic mouse model of disease (Yung et al., 2011)
(Figure 3A). Hydrocephalus was induced by injecting LPA or
blood components into the lateral ventricles, which resulted in
up to 100% incidence of ventriculomegaly. Hydrocephalus was
accompanied by related clinical characteristics, including neuro-
rosette formation, displaced NPCs, cortical disruptions, and
third ventricular and aqueductal occlusions (Fukumizu et al.,
1995; Domı´nguez-Pinos et al., 2005). These phenotypes were
reduced or prevented in an Lpar1 and Lpar2 double null mutant
or by use of pharmacological LPA1/3 antagonism. This and
related disorders initiated by hemorrhage might be amenable
to medical interventions involving LPAR signaling modulators.
Neuropsychiatric Models
Lpar1 null mice display a variety of negative behavioral signs and
cognitive deficits, suggesting the importance of LPA1 signaling in
normal cognition. Neonatal Lpar1 null mice display problems in
olfaction related to suckling as well as pronounced craniofacial
dysmorphism (Contos et al., 2000), a trait commonly seen in
autism (Ploeger et al., 2010). maLpar1 null mice, a spontaneous
variant that arose during colony expansion of the Lpar1 null line in
Ma´laga, Spain, exhibit several negative behavioral signs, in-
cluding generalized anhedonia (Santin et al., 2009), hypersen-
sitivity to stress (Castilla-Ortega et al., 2011), and increased
anxiety (Santin et al., 2009). Lpar1 null mice also display deficits
in prepulse inhibition (PPI) of the startle reflex (Harrison et al.,
2003), a cognitive attention-related test that is significantly
impaired in schizophrenia patients, as well as learning andmem-
ory deficiencies particularly related to spatial memory retention
(Santin et al., 2009), consolidation, and working memory (Cas-
tilla-Ortega et al., 2011).
LPA signaling has additionally been linked to many of the un-
derlying molecular and neurotransmitter pathways involved in
both genetic and environmental risk factors for neuropsychiatric
disorders. Glycogen synthase kinase-3 (GSK3)—a signaling
network node associated with risk factors such as disrupted in
schizophrenia 1 (Disc1), neuregulin 1 (Nrg1), Akt1, and reelin—
is regulated by Lpar1 (Lovestone et al., 2007; Mao et al., 2009).
Additionally, glutamatergic signaling alterations are implicated
in behavioral deficits associated with schizophrenia, autism,
and other related neuropsychiatric disorders (Lin et al., 2012a;
Hadley et al., 2014), and LPA is known to reduce glutamate up-
take involving an LPA1-independent mechanism (Shano et al.,
2008). Modification of LPA1 expression has been linked to
altered miniature excitatory postsynaptic potential (mEPSP) ki-
netics and frequency, inhibitory postsynaptic potential (IPSP)Neuron 85, February 18, 2015 ª2015 Elsevier Inc. 675
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ham et al., 2006; Trimbuch et al., 2009). Lpar1 null mice also
display alterations in serotonin (5-HT) neurotransmitter levels
(Harrison et al., 2003), dysregulation of glutamatergic synap-
ses particularly through regulation of the glutamate receptors
GluR1, GluR3, and the NMDA receptor NR2A/B (Harrison
et al., 2003; Roberts et al., 2005; Musazzi et al., 2011), increases
in hippocampal CaMKII activity (Musazzi et al., 2011), and de-
creases in parvalbumin-positive neurons (Cunningham et al.,
2006). These data present a compelling picture of LPA1-initiated
glutamatergic and GABAergic signaling dysregulation resulting
in negative and cognitive behavioral deficits relevant to schi-
zophrenia, depression, bipolar disorder, and anxiety disorders
(Figure 3B).
The PLA2 enzyme family, composed of at least 15 groups, is
one of the main phospholipases responsible for LPA production.
The activity of distinct forms of PLA2, particularly cytosolic and
intracellular forms, can be significantly increased in first-episode
schizophrenia patients and is strongly associated with structural
brain abnormalities (Smesny et al., 2010). In addition, rats with
knocked-down PLA2 expression show reductions in PPI (Lee
et al., 2009). The removal of a lipid enzyme homolog associated
with LPA degradation and uptake, plasticity-related gene 1
(PRG-1 or LPPR4: lipid phosphate phosphatase-related protein
type 4, reviewed in Strauss and Bra¨uer, 2013), results in epilepsy
in null mice (Trimbuch et al., 2009). Importantly, these seizures
are prevented when LPA2 signaling is also removed, suggesting
a receptor-dependent pathology.
Many environmental risk factors for neuropsychiatric dis-
eases, such as bleeding, infection, and hypoxia, are insults
that overactivate LPA signaling (Eichholtz et al., 1993; Herr
et al., 2011). Cortical LPA administration increased anxiety,
anhedonia, and depression-associated immobility in adult mice
(Castilla-Ortega et al., 2014). These behavioral deficits are similar
to those seen in Lpar1 null mice, suggesting that regulation
of LPA signaling is critical for regulation of certain behaviors.
Indeed, since cortical exposure to high concentrations of LPA
during mid-neurogenesis also induces hydrocephalus, this sug-
gests that either increased or decreased LPAR signaling could
lead to a number of neurological and psychiatric disorders that
might be considered ‘‘hypomorphs’’ of the severe changes
seen in hydrocephalus. It is possible that the timing, severity,
and duration of aberrant LPAR signaling contributes to specific
pathologies, which requires further validation through clinical
studies.
Alzheimer’s Disease
One of the central pathologies in Alzheimer’s disease (AD) is an
abundance of senile plaques and tangles composed of beta-am-
yloid (Ab) and tau aggregates. Increased ATX expression found
in the frontal cortex of Alzheimer’s patients (Umemura et al.,
2006) suggests that altered LPAR signaling might contribute to
the pathology of the disease. LPA enhances site-specific patho-
genic tau phosphorylation, leading to GSK3-mediated growth
cone collapse in neurons (Sayas et al., 1999). LPA also increases
b-secretase activity, leading to elevated Ab production (Shi et al.,
2013). Gintonin, a bioactive fraction isolated from ginseng that
has been reported to improve cognition in AD, is composed of
protein-bound LPA that can activate LPA1-5. Treatment of Ab676 Neuron 85, February 18, 2015 ª2015 Elsevier Inc.transgenic mouse AD models with gintonin has been reported
to attenuate amyloid plaque deposition and prevent long-term
memory impairment, resulting in cognitive dysfunction rescue
(Hwang et al., 2012). It will be important to validate these reports,
including determination of whether there are specific LPARs
involved in Ab plaque formation and cognitive deficits in AD.
Nerve Injury and Pain
LPA signaling is involved in nerve injury and pain responses
through LPARs (reviewed in Ueda et al., 2013) (Figure 3C).
Neuropathic pain, commonly caused by trauma or inflammation
of the nervous system, is modeled using partial sciatic nerve
ligation (PSNL), intrathecal LPA injection, UVB irradiation, or
ischemia-induced pain. Intrathecal LPA injection initiates neuro-
pathic pain inmice (Inoue et al., 2004; Ueda et al., 2013), while de
novo synthesis of LPA through PLA2 and ATX appears to
mediate the initial phases of pain (Ma et al., 2010). Lysoleci-
thin—also known as LPC—is a demyelinating agent (Hall,
1972) that induces neuropathic pain via ATX-mediated conver-
sion into LPA (Inoue et al., 2008b). Notably, Enpp2 heterozygous
null mice that have a 50% decrease in plasma LPA also show a
50% recovery from PSNL-induced pain (Inoue et al., 2008a).
Other types of pain may also be dependent on specific LPA
forms (Ma et al., 2013).
Genetic removal of Lpar1 blocks LPA-induced sequelae
during PSNL injury, demonstrating receptor specificity (Inoue
et al., 2004). Allodynia and demyelination are also reduced using
Rho pathway inhibitors, implicating LPA1-mediated Rho activa-
tion (Inoue et al., 2004). Furthermore, LPA1 activation can induce
a nociceptive response that mediates the release of substance
P, a neuropeptide implicated in inflammation and pain (Renba¨ck
et al., 1999). Intraperitoneal administration of Ki16425, an LPA1/3
antagonist, can block LPA-induced nociception (Ma et al., 2013).
PSNL-induced neuropathic pain can also be blocked in Lpar5
null mice, resulting in decreased phosphorylated cAMP res-
ponse element-binding protein (pCREB) expression in spinal
cord dorsal horn neurons and distinct involvement of cAMP, in-
dependent of LPA1 signaling but requiring LPA5 (Lin et al.,
2012b).
Lipids, including LPA, can indirectly activate or sensitize noci-
ceptors by interacting with TRP or sodium channel families, or by
recruiting immune cells to the site of inflammation. During UVB
radiation-induced inflammatory hyperalgesia, LPA and other
lipids are elevated in the skin, but not in dorsal root ganglia or
dorsal horn (Sisignano et al., 2013). Sensitization of afferent Ab
and Ad fibers are responsible for LPA-induced mechanical allo-
dynia. Moreover, TRPV1 receptors in Ab and Ad fibers are
thought to be involved in the maintenance of LPA-induced allo-
dynia (Ohsawa et al., 2013).
Brain Cancer
LPA signaling may be relevant to cancer by promoting tumor
growth, neovascularization, survival, and metastasis (reviewed
in Tsujiuchi et al., 2014; Yung et al., 2014) (Figure 3D). Aberrant
LPAR expression and signaling in CNS glioblastomas and neuro-
blastomas have been reported (Hoelzinger et al., 2008; Willier
et al., 2013). LPAR1 and ENPP2 are overexpressed in highly
malignant glioblastoma multiforme (GBM) (Kishi et al., 2006).
Metabolism of LPC by ATX may provide a chemotactic source
of LPA, since ENPP2 knockdown in GBM reduces LPC-directed
Neuron
Reviewmigration, inhibits invasion, and enhances tumor radiosensitivity
(Kishi et al., 2006; Hoelzinger et al., 2008; Schleicher et al., 2011).
Induced LPA1, LPA2, or LPA3 signaling stimulates increased cell
motility (Van Leeuwen et al., 2003; Hama et al., 2004; Hayashi
et al., 2012), while in contrast, LPA4 expression in B103 cells
may attenuate pro-migratory LPA1 and LPA2 responses (Lee
et al., 2008).
Dysregulated Rho and Rac signaling appears to correlate with
neural tumor proliferation and invasiveness (Khalil and El-Sibai,
2012), which can be altered by LPAR mechanisms. LPA1 and
LPA2 signaling induces stress fiber formation, cytoskeletal
rearrangement, and cell migration in GBM cells via downstream
Rho/ROCK activation (Manning et al., 2000). ROCK inhibition in
LPAR-expressing tumor cells decreases motility and invasion
(Salhia et al., 2005; Hayashi et al., 2012). This pathway is
balanced and antagonized by Rac1-mediated adhesion and
PI3K signaling (Van Leeuwen et al., 2003; Seasholtz et al.,
2004; Salhia et al., 2005). Other LPA-induced migration mecha-
nisms may involve Ras-MAP kinase signaling and matrix metal-
loproteinases (Annabi et al., 2009; Kato et al., 2012).
Conclusion
Over the past two decades, the roles of LPA signaling have
been progressively defined in the normal developing and adult
nervous system, initiated by the identification of specific, cell-
surface receptors. LPA signaling influences numerous develop-
mental processes, including NPC proliferation, neural and glial
development, proper cell migration, and cell survival. Environ-
mental stressors such as hypoxia, inflammation, and hemor-
rhage that increase LPA signaling have links tomultiple neuropa-
thologies. Genuine therapeutics targeting LPARs are anticipated
in the future, especially in view of the compound known as fingo-
limod, an FDA-approved medicine for treating multiple sclerosis,
which modulates LP (S1P) receptors (Chun and Brinkmann,
2011; Groves et al., 2013), along with the entry of new chemical
entities targeting LPARs into clinical trials for other indications
(Kihara et al., 2014b; Yung et al., 2014). The prospects are
increasingly bright for uncovering new mechanisms and medi-
cines that impact the nervous system through LPA signaling.
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After this Review was completed, Mirendil et al. (2015) was accepted for
publication. This article demonstrates how in vivo exposure to LPA in the
developing mouse brain, which mimics intracerebral bleeding, can produce
postnatal schizophrenia-like changes:
Mirendil, H., Thomas, E.A., De Loera, C., Okada, K., Inomata, Y., and Chun, J.
(2015). LPA signaling initiates schizophrenia-like brain and behavioral changes
in a mouse model of prenatal hemorrhage. Transl. Psychiatry, in press.
